- Stocks
- Pharma & Healthcare
- Hester Biosciences
Hester Biosciences share price
NSE: HESTERBIOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Hester Biosciences at a glance
Hester Biosciences (NSE: HESTERBIO) closed at ₹2,280.00 on 19 Oct 2026, up 1.97% on the day. With a market capitalisation of ₹1,940 Cr, it ranks 1170th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 33.7× trailing earnings, against a return on equity of 8.7% in FY25. Over the past year the share price has risen 31.4%. Its 52-week range is ₹1,239.30 (30 Mar 2026) to ₹2,683.60 (30 Jul 2026); the last close is 15.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹77 Cr (−8.2% year on year) and net profit ₹95 Cr (+482.8%), on a consolidated basis. Promoters held 53.73% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,940 CrRank 1170 on NSE
- P/E (trailing)
- 33.7×
- Price to book
- 3.39×FY25
- EPS (TTM)
- ₹160.95to Q1 FY27
- ROE
- 8.7%FY25
- ROCE
- 9.1%FY25
- Debt to equity
- 0.66FY25
- Net profit margin
- 7.9%FY25
- Book value / share
- ₹369.41FY25
- Dividend payout
- 18.6%FY25
- 52-week high
- ₹2,683.6030 Jul 2026
- 52-week low
- ₹1,239.3030 Mar 2026
- 1-year return
- +31.4%
- RSI (14-day)
- 57.7
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.97% | +9.8% | +0.9% | −8.5% | +31.4% |
Hester Biosciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹84 Cr | ₹63 Cr | ₹82 Cr | ₹84 Cr | ₹71 Cr | ₹77 Cr | ₹100 Cr | ₹77 Cr |
| Revenue YoY | +18.8% | −5.6% | +3.4% | +2.2% | −15.2% | +22.5% | +22.2% | −8.2% |
| Net profit | ₹7 Cr | ₹10 Cr | ₹0 Cr | ₹16 Cr | ₹12 Cr | ₹8 Cr | ₹15 Cr | ₹95 Cr |
| Net profit YoY | +198.8% | +271.2% | −96.1% | +145.1% | +63.7% | −23.3% | +6,287.0% | +482.8% |
| Net margin | 8.9% | 16.5% | 0.3% | 19.3% | 17.2% | 10.3% | 14.7% | 122.6% |
| EPS | ₹9.86 | ₹13.41 | ₹1.82 | ₹20.33 | ₹16.85 | ₹10.94 | ₹19.45 | ₹113.71 |
Hester Biosciences financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹183 Cr | ₹214 Cr | ₹235 Cr | ₹266 Cr | ₹305 Cr | ₹311 Cr |
| Operating profit | ₹41 Cr | ₹53 Cr | ₹53 Cr | ₹36 Cr | ₹27 Cr | ₹35 Cr |
| Net profit | ₹31 Cr | ₹35 Cr | ₹39 Cr | ₹24 Cr | ₹17 Cr | ₹25 Cr |
| EPS (₹) | ₹36.00 | ₹41.00 | ₹46.00 | ₹33.00 | ₹25.00 | ₹34.00 |
| Cash from operations | ₹37 Cr | ₹58 Cr | ₹9 Cr | ₹24 Cr | ₹48 Cr | ₹65 Cr |
| Total debt | ₹76 Cr | ₹83 Cr | ₹165 Cr | ₹185 Cr | ₹182 Cr | ₹133 Cr |
| Shareholders' equity | ₹201 Cr | ₹228 Cr | ₹260 Cr | ₹280 Cr | ₹292 Cr | ₹314 Cr |
Hester Biosciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% |
| Foreign institutions | 0.87% | 0.52% | 0.53% | 0.51% | 0.38% | 0.31% |
| Domestic institutions | 0.02% | 0.02% | 0.00% | 0.01% | 0.00% | 0.00% |
| Non-institutions | 45.38% | 45.73% | 45.74% | 45.75% | 45.89% | 45.95% |
Hester Biosciences vs peers
The listed Pharma & Healthcare companies nearest to Hester Biosciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SAKARSakar Healthcare | ₹919.80 | −4.29% | +156.2% | ₹2,047 Cr | 67.3 | — |
| SYNCOMFSyncom Formulations (India) | ₹21.56 | −2.00% | +26.6% | ₹2,027 Cr | 26.6 | — |
| HESTERBIOHester Biosciences | ₹2,280.00 | +1.97% | +31.4% | ₹1,940 Cr | 33.7 | — |
| BETABeta Drugs | ₹1,736.30 | −3.00% | +0.3% | ₹1,925 Cr | 42.5 | — |
| FISCHERFischer Medical Ventures | ₹28.21 | −3.56% | −71.0% | ₹1,846 Cr | 62.7 | — |
| WINDLASWindlas Biotech | ₹892.20 | −2.24% | −2.1% | ₹1,841 Cr | 28.6 | — |
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
Ask anything about Hester Biosciences
Pivot answers on the live chart with evidence you can check, and tests strategies against HESTERBIO's own history. Try: “Why has HESTERBIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on HESTERBIO over five years” · “Compare HESTERBIO with SAKAR on margins and valuation”
Frequently asked questions about Hester Biosciences
What is the share price of Hester Biosciences today?
Hester Biosciences (NSE: HESTERBIO) last closed at ₹2,280.00 on 19 Oct 2026. Its 52-week high is ₹2,683.60 and its 52-week low is ₹1,239.30.
What is the market cap of Hester Biosciences?
Hester Biosciences' market capitalisation is ₹1,940 Cr (₹1,940 Cr) at the 19 Oct 2026 close, ranking 1170th among the NSE companies Pivot tracks.
What is the P/E ratio of Hester Biosciences?
Hester Biosciences trades at a trailing P/E of 33.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 42.5.
What is the ROE and ROCE of Hester Biosciences?
Return on equity was 8.7% in FY25 and return on capital employed was 9.1% in FY25 (consolidated figures).
Is Hester Biosciences a debt-free company?
No. Hester Biosciences' debt-to-equity ratio was 0.66 in FY25, with total debt of ₹133 Cr.
What were Hester Biosciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Hester Biosciences reported revenue of ₹77 Cr, −8.2% year on year, and net profit of ₹95 Cr, +482.8% year on year.
How has Hester Biosciences stock performed over the last year?
Hester Biosciences' share price has risen 31.4% over the past year, −8.5% over three months and +0.9% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Hester Biosciences?
As of 30 Jun 2026: promoters 53.73%, foreign institutions 0.31%, domestic institutions 0.00%, non-institutions 45.95%.
Who are Hester Biosciences' competitors?
The listed Pharma & Healthcare companies closest to Hester Biosciences by market cap are Sakar Healthcare, Syncom Formulations (India), Beta Drugs, Fischer Medical Ventures, Windlas Biotech and Titan Biotech.
Is Hester Biosciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Hester Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HESTERBIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text